文献速递核素与放射性配体治疗肿瘤 PET/CT

放射性混合体177Lu-rhPSMA-10.1治疗转移性前列腺癌的首个安全性与疗效数据

First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
PubMed 文献 · J Nucl Med · 2024-03-01

该研究报告了4例PSMA阳性转移性前列腺癌患者接受177Lu-rhPSMA-10.1治疗(每周期7.4-7.7 GBq,共4-6周期,总活度29.6-59.4 GBq)的疗效与安全性。前列腺特异性抗原(PSA)分别下降100%、99%、88%和35%,2例患者无进展生存期未达到(随访24和18个月),另2例分别为15和12个月。无严重不良事件报告,结论认为该药显示出鼓舞人心的初步疗效且耐受良好,正式临床试验正在进行中(NCT05413850)。

要点

  • 4例PSMA阳性转移性前列腺癌患者接受177Lu-rhPSMA-10.1治疗,PSA下降35%-100%。
  • 2例患者无进展生存期未达到(随访24和18个月),另2例为15和12个月。
  • 未报告严重不良事件,1例患者在2年随访时维持持续完全缓解。

核心结论

  • 177Lu-rhPSMA-10.1显示出鼓舞人心的初步疗效且耐受良好,正式临床试验正在进行中以前瞻性评估其潜力(NCT05413850)。

研究设计与样本

  • 4例连续入组的PSMA阳性转移性前列腺癌患者接受最多6周期177Lu-rhPSMA-10.1治疗,每周期7.4-7.7 GBq。
  • 评估疗效(按前列腺癌工作组3标准评估PSA反应及按PSMA PET/CT反应评估标准评估)、无进展生存期和总生存期,不良事件从首次给药记录至治疗后16-24个月。

主要发现

  • 患者接受总活度29.6-59.4 GBq(4-6周期)。
  • PSA分别下降100%、99%、88%和35%。
  • 2例患者无进展生存期未达到(随访24和18个月),另2例分别为15和12个月。
  • 1例患者在2年随访时维持持续完全缓解,所有患者在末次数据收集时均存活。
  • 未报告严重不良事件。

局限性

  • 本文为初步数据,样本量为4例连续患者。
  • 正式临床试验正在进行中以前瞻性评估其潜力(NCT05413850)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We recently published the first dosimetry data, to our knowledge, for the radioligand therapy agent 177Lu-rhPSMA-10.1, providing an intrapatient comparison with 177Lu-PSMA-I&T in patients with metastatic prostate cancer. Here, we report efficacy and safety findings from these patients. Methods: Four consecutive patients with prostate-specific membrane antigen (PSMA)-positive metastatic prostate cancer received up to 6 cycles of 177Lu-rhPSMA-10.1 (7.4-7.7 GBq per cycle). Efficacy (prostate-specific antigen response according to Prostate Cancer Working Group 3 criteria and the Response Evaluation Criteria in PSMA PET/CT), progression-free survival, and overall survival were evaluated. Adverse events were recorded from the first dose until 16-24 mo after treatment. Results: The patients received a total activity of 29.6-59.4 GBq (4-6 cycles). Prostate-specific antigen was reduced by 100%, 99%, 88%, and 35%. Progression-free survival was not reached for 2 patients at 24 and 18 mo of follow-up and was 15 and 12 mo for the other 2 patients. One patient had a sustained complete response with 2 y of follow up. All patients were alive at the last time point of data collection. No serious adverse events were reported. Conclusion: 177Lu-rhPSMA-10.1 demonstrated encouraging preliminary efficacy and was well tolerated. Formal clinical trials are now under way to evaluate its potential prospectively (NCT05413850).

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dierks A, Gäble A, Rinscheid A, et al. First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer. J Nucl Med. 2024. PMID: 38164586. doi:10.2967/jnumed.123.266741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。